Cisplatin, fluorouracil, interferon-α, and radiation as adjuvant therapy for resected pancreatic cancer: Is there a future for this regimen and/or should we change our approach to research and treatment of patients with pancreatic cancer?

Annals of Surgery

Volumn 248, Issue 2, 2008, Pages 152-153

  Pisters, Peter W T ^a   Evans, Douglas B ^a  

^a UNIVERSITY OF TEXAS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; CISPLATIN; FLUOROURACIL; GEMCITABINE; ALPHA1 INTERFERON; ANTINEOPLASTIC AGENT; INTERFERON ALPHA-1;

CANCER CENTER; CLINICAL TRIAL; EDITORIAL; EXTERNAL BEAM RADIOTHERAPY; FEBRILE NEUTROPENIA; FOLLOW UP; GASTROINTESTINAL TOXICITY; HEALTH CARE DELIVERY; HOSPITALIZATION; HUMAN; MEDICAL SOCIETY; MORTALITY; MULTIMODALITY CANCER THERAPY; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PANCREAS ADENOCARCINOMA; PATIENT SELECTION; PRIORITY JOURNAL; PROGNOSIS; QUALITY OF LIFE; TREATMENT DURATION; ADJUVANT CHEMOTHERAPY; ADJUVANT THERAPY; CANCER STAGING; FEMALE; FORECASTING; MALE; METHODOLOGY; NOTE; PANCREAS RESECTION; PANCREAS TUMOR; PATHOLOGY; RADIATION DOSE; RESEARCH; RISK ASSESSMENT; SENSITIVITY AND SPECIFICITY; SURVIVAL;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CHEMOTHERAPY, ADJUVANT; CISPLATIN; COMBINED MODALITY THERAPY; FEMALE; FLUOROURACIL; FORECASTING; HUMANS; INTERFERON-ALPHA; MALE; NEOPLASM STAGING; PANCREATECTOMY; PANCREATIC NEOPLASMS; PROGNOSIS; RADIOTHERAPY DOSAGE; RADIOTHERAPY, ADJUVANT; RESEARCH; RISK ASSESSMENT; SENSITIVITY AND SPECIFICITY; SURVIVAL ANALYSIS;

EID: 49849088623     PISSN: 00034932     EISSN: 15281140     Source Type: Journal    
DOI: 10.1097/SLA.0b013e3181820d35     Document Type: Editorial

References (4)

1. Linehan DC, Tan MCB, Strasberg SM, et al. Adjuvant interferon-based chemoradiation followed by gemcitabine for resected pancreatic adenocarcinoma: a single-institution phase II study. Ann Surg. 2008;248:145- 151.
2. Picozzi VJ, Traverso LW. The Virginia Mason approach to localized pancreatic cancer. Surg Oncol Clin N Am. 2004;13:663-674.
3. Picozzi VJ, AbramsRA, Traverso LW, etal. ACOSOGZ05031: report on a multicenter, phase II trial for adjuvant therapy of resected pancreatic cancer using cisplatin, 5-FU, and alpha-interferon. Proc Am Soc Clin Oncol. 2008;p. 214S, abstract 4505.
4. Regine WF, Winter KA, Abrams RA, et al. Fluorouracil vs gemcitabine chemotherapy before and after fluorouracil-based chemoradiation following resection ofpancreatic adenocarcinoma: a randomized controlled trial. JAMA. 2008;299:1019-1026.